Stopping RAS Inhibitors May Worsen Outcomes in CKD
FRIDAY, Jan. 15, 2021 -- The decision to stop renin-angiotensin system (RAS) inhibitor therapy in patients with advanced chronic kidney disease (CKD) should take into account both cardiovascular risk and the risk for kidney replacement therapy,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 15, 2021 Category: Pharmaceuticals Source Type: news

Stopping Common Heart Meds Could Be Risky for Kidney Patients
THURSDAY, Jan. 14, 2021 -- Patients with chronic kidney disease who stop using a class of common blood pressure medications may lower their risk for dialysis, but they also raise their odds of cardiovascular disease, a new study finds. The blood... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 14, 2021 Category: General Medicine Source Type: news

Metformin use reduces risk of death for patients with COVID-19 and diabetes
(University of Alabama at Birmingham) Use of the diabetes drug metformin -- before a diagnosis of COVID-19 -- is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a racially diverse study at the University of Alabama at Birmingham. Diabetes is a significant comorbidity for COVID-19. This beneficial effect remained, even after correcting for age, sex, race, obesity, and hypertension or chronic kidney disease and heart failure. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 14, 2021 Category: Infectious Diseases Source Type: news

US-FDA-grants-priority-review-New-Drug-Application-finerenone-treat-patients-chronic-kidney-disease
(Source: Bayer Company News)
Source: Bayer Company News - January 12, 2021 Category: Pharmaceuticals Source Type: news

First-degree relative with kidney disease increases disease risk by three-fold
(National Kidney Foundation) In a large population-based family study, family history of kidney disease was strongly associated with increased risk of chronic kidney disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 12, 2021 Category: International Medicine & Public Health Source Type: news

Updated advice on COVID-19 vaccination in pregnancy and women who are breastfeeding, RCOG
The Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca's COVID-19 vaccine for use. The Joint Committee on Vaccination and Immunisation (JCVI) has also published its latest advice for the priority groups to receive the Oxford University/AstraZeneca and the Pfizer/BioNTech vaccines. This includes updated advice for pregnant and breastfeeding women who meet other criteria for priority vaccination. The JCVI confirms that although the available data do not indicate any safety concern or harm to pregnancy, there is insuf...
Source: Current Awareness Service for Health (CASH) - December 31, 2020 Category: Consumer Health News Source Type: news

Stopping RAS inhibitors tied to worse outcomes in patients with chronic kidney disease
(Karolinska Institutet) Small studies have suggested that a group of medications called RAS inhibitors may be harmful in persons with advanced chronic kidney disease, and physicians therefore often stop the treatment in such patients. Researchers at Karolinska Institutet now show that although stopping the treatment is linked to a lower risk of requiring dialysis, it is also linked to a higher risk of cardiovascular events and death. The results are published inThe Journal of the American Society of Nephrology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 29, 2020 Category: International Medicine & Public Health Source Type: news

Fine Particulate Matter Linked to Increased Prevalence of CKD
WEDNESDAY, Dec. 23, 2020 -- Fine particulate matter (PM2.5) is associated with an increased prevalence of chronic kidney disease (CKD) and albuminuria in the general population in China, according to a study published online Dec. 17 in the Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 23, 2020 Category: Pharmaceuticals Source Type: news

After nearly $1 billion and 27 years, S.F. biotech now must wait another 90 days for 1st FDA decision
A Food and Drug Administration decision on whether to approve a drug from FibroGen Inc. to treat anemia in chronic kidney disease patients was delayed Friday for 90 days. San Francisco-based FibroGen (NASDAQ: FGEN) and partner AstraZeneca plc (NASDAQ: AZN) expected a decision by Sunday, but the FDA said it required additional analyses of existing clinical trial results for the drug, called roxadustat. The agency moved the decision date to March 20. FibroGen CEO En rique Conterno said in a statement… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 21, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Air Pollution Takes a Toll on Your Kidneys
THURSDAY, Dec. 17, 2020 -- Tiny particles of air pollution were already known to raise people's risk of developing heart and lung disease, but a new study suggests they might also raise the risk of developing chronic kidney disease. Researchers from... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 17, 2020 Category: General Medicine Source Type: news

FGF23, frailty, and falls in SPRINT - Jovanovich A, Ginsberg C, You Z, Katz R, Ambrosius WT, Berlowitz D, Cheung AK, Cho M, Lee AK, Punzi H, Rehman S, Roumie C, Supiano MA, Wright CB, Shlipak M, Ix JH, Chonchol M.
BACKGROUND/OBJECTIVES: Chronic kidney disease (CKD) is associated with frailty. Fibroblast growth factor 23 (FGF23) is elevated in CKD and associated with frailty among non-CKD older adults and individuals with human immunodeficiency virus. Whether FGF23 i... (Source: SafetyLit)
Source: SafetyLit - December 10, 2020 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Kidney disease leading risk factor for COVID-related hospitalization
(Geisinger Health System) An analysis of Geisinger's electronic health records has revealed chronic kidney disease to be the leading risk factor for hospitalization from COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 2, 2020 Category: Infectious Diseases Source Type: news

Weighing in on chronic kidney disease
(Source: ScienceNOW)
Source: ScienceNOW - November 26, 2020 Category: Science Authors: Nusinovich, Y. Tags: twil Source Type: news

AHA: Sotagliflozin Beneficial for T2DM With Heart Failure
WEDNESDAY, Nov. 25, 2020 -- Sotagliflozin is beneficial for the treatment of type 2 diabetes in patients with recent worsening heart failure as well as in patients with chronic kidney disease, according to two studies published online Nov. 16 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 25, 2020 Category: Pharmaceuticals Source Type: news

Finerenone's Heart Benefits Hold in T2D Without CVD: FIDELIO-DKD Finerenone's Heart Benefits Hold in T2D Without CVD: FIDELIO-DKD
The nonsteroidal mineralocorticoid receptor antagonist showed cardiovascular benefits in patients with type 2 diabetes and chronic kidney disease, with or without CVD, a phase 3 trial shows.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 24, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Non-invasive electrolyte levels' measuring method can prevent sudden cardiac death
(Kaunas University of Technology) Researchers from Kaunas University of Technology (KTU), Lithuania came up with the idea on how to measure fluctuating blood potassium levels non-invasively, through electrocardiogram. The researchers claim that their method may become a digital biomarker in the future for managing electrolyte levels. This would be a huge step towards preventing potentially life-threatening conditions among people who suffer from chronic kidney disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 23, 2020 Category: Biology Source Type: news

FDA Authorizes Emergency Use Of Regeneron ’ s COVID Treatment Taken By President Trump
(CNN) — The US Food and Drug Administration on Saturday issued an emergency use authorization for Regeneron’s antibody cocktail to treat Covid-19 in high-risk patients with mild to moderate disease. President Donald Trump received the therapy, called REGEN-COV2, when he was hospitalized for coronavirus. The treatment has to be infused into the bloodstream and is meant to mimic an immune response to infection. The cocktail reduced Covid-19-related hospitalizations and emergency room visits in some patients within 28 days of treatment, the FDA said in a news release. Regeneron’s chief ex...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 22, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Covid-19 Boston, MA Health Syndicated CBSN Boston CNN Coronavirus President Trump Coronavirus Regeneron Source Type: news

Bristol secures £ 45M to advance gene therapy treatment of chronic kidney diseases
The University of Bristol has secured a £ 45million deal to advance its groundbreaking gene therapy technology for chronic kidney diseases. The commitment, made by healthcare company Syncona Ltd to Bristol spin-out Purespring Therapeutics, aims to address a global unmet need for renal conditions in one of the largest single investments made to a new UK university biotech company. (Source: University of Bristol news)
Source: University of Bristol news - November 19, 2020 Category: Universities & Medical Training Tags: Health, Research; Faculty of Life Sciences, Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news

17.11.20: Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020
Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular diseaseIn the FIDELIO-DKD Phase III study among patients with chronic kidney disease and type 2 diabetes, overall finerenone significantly lowered the combined risk of cardiovascular events, with comparable treatment efficacy for patients with or without history of cardiovascular disease / People with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone / Finere...
Source: Bayer IR Newsfeed: Events - November 17, 2020 Category: Pharmaceuticals Source Type: news

New medication helps heart health in people with chronic kidney disease, Type 2 diabetes
(American Heart Association) Results of a large, international clinical trial on the novel medication finerenone indicate it reduced the rate of death, heart attack, stroke and hospitalization for heart failure among patients with chronic kidney disease and Type 2 diabetes. Finerenone helped patients with chronic conditions improve their heart health, regardless of if they had a history of cardiovascular disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2020 Category: International Medicine & Public Health Source Type: news

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
(American Heart Association) Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.Researchers say the results of this randomized clinical trial provide evidence that SGLT2 inhibitors should be part of the standard of care for people with Type 2 diabetes and chronic kidney disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2020 Category: International Medicine & Public Health Source Type: news

SCORED and SOLOIST Trials Add to Evidence for Treating Diabetes with SGLT2 Inhibitors
• SCORED trial of patients with diabetes and chronic kidney disease is first trial of an SGLT2 inhibitor to show benefit across the full range of albuminuria • SOLOIST is the first trial to show an SGLT2 inhibitor is safe to start in patients hospit (Source: BWH News)
Source: BWH News - November 16, 2020 Category: Hospital Management Source Type: news

Epilepsy risk among survivors of intensive care unit hospitalization for sepsis
CONCLUSION(S): In this real-world analysis, sepsis survivors, particularly those who are younger and have chronic kidney disease, are at significantly higher epilepsy risk. These findings indicate that sepsis may be an unrecognized epilepsy risk factor. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - November 13, 2020 Category: Consumer Health News Source Type: news

Highlights in CKD From ASN Kidney Week 2020 Highlights in CKD From ASN Kidney Week 2020
Dr Jeffrey Silberzweig highlights chronic kidney disease presentations from ASN Kidney Week 2020, including results from the DAPA-CKD trial, data on HIF inhibitors, and COVID-19 telenephrology.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 12, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Depressive disorders are associated with risk of falls in people with chronic kidney disease - Kistler BM, Khubchandani J, Bennett P, Wilund KR, Sosnoff J.
OBJECTIVES: People with chronic kidney disease (CKD) are at increased risk for falls and fall-related injuries. Depressive disorders (DEP) are common in individuals with CKD and may increase the risk of falls and fall-related injuries. However, not much is... (Source: SafetyLit)
Source: SafetyLit - November 11, 2020 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Moderate-to-Severe CKD Tied to Worse VTE Outcomes Moderate-to-Severe CKD Tied to Worse VTE Outcomes
A registry study of patients with venous thromboembolism (VTE) suggests moderate-to-severe chronic kidney disease (CKD) is associated with greater risks of death, VTE recurrence and major bleeding compared to mild or no CKD.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - November 10, 2020 Category: Intensive Care Tags: Cardiology News Source Type: news

09.11.20: Not intended for U.S. and UK Media
Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetesRegulatory submissions based on positive data from Phase III FIDELIO-DKD study recently published in the New England Journal of Medicinemehr ... (Source: Bayer IR Newsfeed: Events)
Source: Bayer IR Newsfeed: Events - November 10, 2020 Category: Pharmaceuticals Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need f...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

New conditions added to shielded patient list ahead of England-wide lockdown
Adults with Down's syndrome and those with stage 5 chronic kidney disease should be added to the shielded patient list, NHS England has told practices, ahead of the nationwide lockdown this week. (Source: GP Online News)
Source: GP Online News - November 3, 2020 Category: Primary Care Tags: Coronavirus Source Type: news

Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups Benefits of SGLT2 Inhibitors Seen Across Patient Subgroups
The benefits of SGLT2 inhibitors are seen in patients with heart failure and in those with chronic kidney disease, data from two pivotal trials, EMPEROR-Reduced and DAPA-CKD, show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 30, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

CVDPREVENT: A national primary care audit
CVDprevent is a national primary care audit to support professionally led quality improvement in the diagnosis and management of six high risk conditions that cause stroke, heart attack and dementia: atrial fibrillation (AF), high blood pressure, high cholesterol, diabetes, non-diabetic hyperglycaemia and chronic kidney disease. (Source: NHS Networks)
Source: NHS Networks - October 30, 2020 Category: UK Health Source Type: news

ASN: Finerenone May Slow Progression in CKD With T2DM
MONDAY, Oct. 26, 2020 -- Finerenone results in a lower risk for chronic kidney disease (CKD) progression in patients with CKD and type 2 diabetes, according to a study published online Oct. 23 in the New England Journal of Medicine to coincide with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 26, 2020 Category: Pharmaceuticals Source Type: news

New model predicts which patients with kidney disease may develop heartbeat irregularities
(American Society of Nephrology) * A new model that incorporates a type of artificial intelligence can accurately predict which individuals with chronic kidney disease face a high risk of developing atrial fibrillation.* Results from the study will be presented online during ASN Kidney Week 2020 Reimagined October 19-October 25. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2020 Category: International Medicine & Public Health Source Type: news

23.10.20: Not intended for U.S. and UK Media - Data from Phase III FIDELIO-DKD study presented at the American Society of Nephrology (ASN)'s Kidney Week 2020
Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes / Finerenone specifically addresses MR overactivation, a key driver of disease progression / Despite guideline-directed therapies, patients with chronic kidney disease and type 2 diabetes remain at high risk of progression to kidney failure and cardiovascular events / Results...
Source: Bayer IR Newsfeed: Events - October 23, 2020 Category: Pharmaceuticals Source Type: news

Decision on Race Multiplier in CKD in Blacks'Has Real Consequences'Decision on Race Multiplier in CKD in Blacks'Has Real Consequences '
Dropping the eGFR multiplier for African Americans produced a 33% hike in those assigned to a more severe stage of chronic kidney disease. But whether or not to keep the adjustment remains unclear, say experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 23, 2020 Category: Consumer Health News Tags: Nephrology News Source Type: news

Removing Race Classifier Would Impact Care in Blacks With CKD
TUESDAY, Oct. 20, 2020 -- About one in three African American patients with chronic kidney disease (CKD) would be reclassified to a more severe CKD stage if the race classifier were removed from the Chronic Kidney Disease Epidemiology Collaboration... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 20, 2020 Category: Pharmaceuticals Source Type: news

Children with chronic kidney disease have outsized health burden
(Michigan Medicine - University of Michigan) Chronically ill children with kidney disease may spend more time in the hospital, incur larger health care costs and have a higher risk of death compared to pediatric patients hospitalized for other chronic conditions, a new study suggests. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 20, 2020 Category: International Medicine & Public Health Source Type: news

Study Reveals the Influence of Race Correction in Kidney Disease Care
Removing ‘race multiplier’ factor would reclassify 1-in-3 Black patients to a more severe chronic kidney disease stage (Source: BWH News)
Source: BWH News - October 15, 2020 Category: Hospital Management Source Type: news

Hospital Outcomes Worse for Children With Chronic Kidney Disease
TUESDAY, Oct. 13, 2020 -- Among children who are hospitalized, pediatric chronic kidney disease (CKD) is associated with longer length of stay (LOS) and increased costs compared with other chronic illnesses, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 13, 2020 Category: Pharmaceuticals Source Type: news

12.10.20: Not intended for U.S. and UK Media - American Society of Nephrology (ASN)'s Kidney Week 2020 Reimagined:
Finerenone Phase III FIDELIO-DKD study in chronic kidney disease and type 2 diabetes to be presented as late-breaking clinical trial at ASN 2020FIDELIO-DKD is the first large contemporary positive outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) with a primary composite endpoint consisting exclusively of kidney-specific outcomes / Finerenone, a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist, demonstrated positive renal and cardiovascular outcomes in patients with CKD and T2D / Preclinical data on finerenone, as well as a range of post...
Source: Bayer IR Newsfeed: Events - October 13, 2020 Category: Pharmaceuticals Source Type: news

Quick Hospitalization Linked to Worse Outcomes in COVID-19 Quick Hospitalization Linked to Worse Outcomes in COVID-19
Patients presenting within 3 days after symptom onset tended to be older and were more likely to have hypertension and chronic kidney disease than those admitted after 1 week.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 8, 2020 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news

Certain pre-existing conditions may double, triple mortality risk for COVID-19
(Penn State) A large, international study of COVID-19 patients confirmed that cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease, stroke and cancer can increase a patient's risk of dying from the virus. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 8, 2020 Category: International Medicine & Public Health Source Type: news

Kidney function and other factors and their association with falls : the screening for CKD among older people across Europe (SCOPE) study - Britting S, Artzi-Medvedik R, Fabbietti P, Tap L, Mattace-Raso F, Corsonello A, Lattanzio F, Arnl öv J, Carlsson AC, Roller-Wirnsberger R, Wirnsberger G, Kostka T, Guligowska A, Formiga F, Moreno-Gonzalez R, Gil P, Martinez SL, Kob R, Melzer I, Freiberger E, SCOPE investigators.
BACKGROUND: Reduced kidney function has become a major public health concern, especially among older people, as Chronic Kidney Disease (CKD) is associated with increased risk of end stage renal disease and mortality. Falls are a serious negative health out... (Source: SafetyLit)
Source: SafetyLit - October 5, 2020 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

CEUS liver guidelines get first update in 8 years
The guidelines for contrast-enhanced ultrasound (CEUS) of the liver received...Read more on AuntMinnie.comRelated Reading: Review: CEUS bests CT, MRI for liver disease CEUS helps predict chronic kidney disease progression Ultrasound software predicts cancer treatment success 5 steps to safe scanning with ultrasound during COVID-19 Societies renew call to pull ultrasound contrast warning (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 2, 2020 Category: Radiology Source Type: news

TAVR and Chronic Kidney Disease: An Emerging Odd Couple TAVR and Chronic Kidney Disease: An Emerging Odd Couple
Although CKD patients and physicians may hesitate to embrace TAVR given the perceived risks of worsening renal function, data suggest that may not be the case for most.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 30, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

AHA Statement Highlights Cardiorenal Benefit of Diabetes Drugs AHA Statement Highlights Cardiorenal Benefit of Diabetes Drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against heart disease and kidney disease progression, the AHA says.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 28, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Your neighborhood may raise your risk of chronic kidney disease
(Drexel University) A neighborhood's overall socioeconomic status, including income and education-level, may influence its residents' risk of chronic kidney disease, according to a study recently published in SSM Population Health by researchers from Drexel University's Dornsife School of Public Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 23, 2020 Category: International Medicine & Public Health Source Type: news

Diet posttranslationally modifies the mouse gut microbial proteome to modulate renal function
Associations between chronic kidney disease (CKD) and the gut microbiota have been postulated, yet questions remain about the underlying mechanisms. In humans, dietary protein increases gut bacterial production of hydrogen sulfide (H2S), indole, and indoxyl sulfate. The latter are uremic toxins, and H2S has diverse physiological functions, some of which are mediated by posttranslational modification. In a mouse model of CKD, we found that a high sulfur amino acid–containing diet resulted in posttranslationally modified microbial tryptophanase activity. This reduced uremic toxin–producing activity and ameliorate...
Source: ScienceNOW - September 16, 2020 Category: Science Authors: Lobel, L., Cao, Y. G., Fenn, K., Glickman, J. N., Garrett, W. S. Tags: Medicine, Diseases, Microbiology reports Source Type: news

Good Lifestyle Choices Prevent Kidney as Well as CV Disease Good Lifestyle Choices Prevent Kidney as Well as CV Disease
Many of the same lifestyle choices recommended for cardiovascular disease prevention now shown to also prevent chronic kidney disease.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - September 16, 2020 Category: Primary Care Tags: Nephrology News Source Type: news

COVID-19 Takes Heavy Toll on Kidneys
The study authors warned that doctors should prepare for a significant rise in chronic kidney disease cases due to the pandemic. (Source: WebMD Health)
Source: WebMD Health - September 14, 2020 Category: Consumer Health News Source Type: news